



Alzheimer's disease

Syndicated Thought Leader Insight

Thought Leader Insight & Analysis Report Alzheimer's Disease Q2 2010

Therapeutic Class:	CNS Disorders
Focus Area:	Alzheimer's disease
Specialty/Location:	Neurologists/N. America
Number of Interviews:	6
Number of Pages:	143
Publication Date:	May 2010
Principal Authors:	Tricia L. Hanlon Kim Grant Jeffrey D. Berk, Ph.D., MBA
Product Code:	MCADQ210-18
Pricing:	\$7,500
Order Info:	www.medpredict.com or call (513) 271-1924

Abstract: Thought leaders who treat Alzheimer's disease face multiple challenges in their effort to improve the lives of patients who have or will have dementia. Just as a cardiologist would do to prevent a heart attack in a patient with high blood pressure and high cholesterol, the neurologist or gerontologist must be able to identify people who are at risk of developing mild cognitive impairment and progressing on to Alzheimer's disease, and treat them prophylactically. For patients with more advanced disease, new therapies are needed to slow degeneration, enhance cognitive function and protect the remaining neuronal structure. For both symptomatic and asymptomatic patients, diagnostics are needed to track the effectiveness of these new therapeutics.

In this report, MedPredict's experts describe the clinical progress of the most interesting therapeutic and diagnostic candidates in achieving these goals. The Panel covers active and passive immunologic approaches that hold promise in prevention of Alzheimer's disease and treatment at the earliest stages of dementia. They rank the most promising small molecules and antibodies that are targeting amyloid and plaques, offering their opinions on γ -secretase inhibitors and modulators, β -secretase inhibitors, Tau inhibitors, cardiovascular agents, anti-amyloids and aggregation inhibitors, mTOR inhibitors, SIRT-1, Liver X, metal chelators and drugs specifically designed to enhance mental function.

As part of this Panel we asked our Thought Leaders to engage in a thought exercise to designate their "fantasy formulary", comprised of the top seven therapeutics, currently in the development pipeline, that they want to see available for use. The Panel's responses are just as enlightening regarding what they would NOT put on their fantasy formularies. This is the second year we've conducted this exercise and we provide both years' results for comparison. The other aims of this Panel were to review progress in the development of diagnostics and imaging technology, and to help shed light on current and future reimbursement policy.

Drugs/Companies Discussed:

Company	Compound	Brand
Abbott	ABT-089	
Allon	AL-108 (NAP; NAPVSIPQ)	
Astellas / CoMentis	CTS-21166	
Ariad	ridaforolimus	
AstraZeneca / Banner	[18F]-AZD4694	
AstraZeneca / Takeda	candesartan	Atacand
Avid	AV45	
Baxter	IVIg	Gammagard
Bayer-Schering / Avid Radiopharmaceuticals	BAY949172 (¹⁸ F-AV-1/ZK)	
Boehringer Ingelheim / Ablynx	vaccine	
Bristol-Myers Squibb	BMS-708163	
Ceregene	CERE-110; AAV-NGF	
Elan / Transition Therapeutics / AZ	ELND005 (scyllo-inositol; AZD-103)	
Elan / J&J / Pfizer	bapineuzumab ACC-001	
Eisai	E-2012	
GE Healthcare	GE-067 / AH-110690 (¹⁸ F-6-OH- BTA-1	
GlaxoSmithKline	933776A SIRT-1 (acquisition of Sirtris)	
Lilly	solanezumab; LY2062430 BACE inhibitor	
Lilly / Elan	semagacestat; LY-450139	
Merck	MK-0752 V950 BACE inhibitor	
Noscira / Zeltia	NP-12; tideglusib	Nypta
Novartis	CAD-106	
Pfizer	PF-4360365 (RN1219) begacestat (GSI-953)	
Pfizer / Medivation	dimebolin	Dimebon
Prana	PBT2	
TauRx	methylthioninium chloride	Rember
Transtech / Pfizer	TTP-854	

Table of Contents

EXECUTIVE SUMMARY 4

Fantasy Formulary - Ground Rules and Scoring	6
Results	7
Table 1A: Preferred Product Classes (2010)	7
Table 1B: Preferred Product Classes (2009)	8
Table 2A: Individual Thought Leader Rankings (2010).....	9
Table 2B: Individual Thought Leader Rankings (2009).....	10
Table 3A: Most Frequent Favorably Mentioned Drugs (2010)	11
Table 3B: Most Frequently Mentioned Drugs (2009)	12
Fantasy Formulary Discussion	13
General Comments.....	13
Preferred Product Classes.....	14

KEY FINDINGS 16

Biomarkers / Surrogate Outcomes / Diagnostics	16
Imaging Agents	20
AV-45 (Avid)	21
[18F]-AZD4694 (AstraZeneca / Banner Alzheimer's Institute).....	23
PIB PET (¹¹ C-6-OH-BTA-1; U. Pittsburgh / GE Healthcare)	24
Pipeline Therapeutics	29
γ-Secretase Inhibitors	29
semagacestat (LY-450139)	29
BMS-708163 (Bristol-Myers Squibb).....	31
begacestat (GSI-953; Pfizer).....	36
γ-Secretase Modulators	37
E-2012 (Eisai).....	39
Passive Immunotherapy	40
bapineuzumab (Elan / Wyeth / Pfizer).....	42
solanezumab (Lilly)	52
PF-4360365 (RN1219; Pfizer)	55
933776A (GlaxoSmithKline)	55
Gammagard (IVIg; Baxter).....	56
Active Immunization.....	58
CAD-106 (Novartis / Cytos)	64
ACC-001 (Elan / Pfizer)	65
V950 (Merck)	66
vaccine (Boehringer Ingelheim / Ablynx).....	66
Tau Phosphorylation Inhibition / GSK3 / mTOR	66
Rember (methylthioninium chloride; TauRx).....	68
NP-12; tideglusib, Nypta® (Noscira / Zeltia).....	70
ridaforolimus (Ariad).....	70
β-Secretase Inhibitors.....	71

Lilly	73
CTS-21166; (CoMentis / Astellas).....	73
TTP-854 (TransTech)	74
Nerve Growth Factor	74
CERE-110; AAV-NGF (Ceregene)	74
Cardiovascular	75
Atacand; candesartan (AstraZeneca / Takeda)	75
Liver X.....	78
vasoactive intestinal peptide	80
Davunetide AL-108 (NAP; NAPVSIQ; Allon)	80
Aggregation Inhibitor.....	81
ELND005 (scyllo-inositol; AZD-103; Elan / Transition Therapeutics)	81
SIRT-1	83
SRT-501 / SRT-2104 / SRT-2379 (GlaxoSmithKline / Sirtris).....	83
Metal Chelation	85
PBT-2 (Prana)	85
Symptomatic Benefit - alpha-7 nicotinic acetylcholine agonist.....	86
ABT-089 (Abbott)	88
Symptomatic Benefit / Mitochondrial	88
Dimebon (dimebolin; Pfizer / Medivation)	88
Insulin Sensitizers / RAGE	89
TTP-488 (RAGE Inhibitor); TransTec / Pfizer	89
THOUGHT-LEADER DISCUSSIONS	91
Interview CNS02434.....	91
Interview CNS02435.....	100
Interview CNS02436.....	109
Interview CNS02437.....	117
Interview CNS02438.....	125
Interview CNS02439.....	135

